Bigot et al constructed the GRIm score based on LDH, NLR, and albumin (ALB) as the inclusion standard for phase I clinical trials of patients with advanced tumors.[15] The GRIm score is widely used in clinical immunotherapy or non-immunotherapy for various solid tumors, such as small cell lung cancer.[16] non-small cell lung cancer[12,17]and esophageal cancer,[18] and its role of prognosis evaluation has been confirmed. The gene discussed is ALB; the disease is non-small cell lung carcinoma.